Publications
Below you can find a list of our published research.
Below you can find a list of our published research.
511 results
Cited 4 times since 1987 (0.1 per year) source: EuropePMC
Cancer treatment reports, Volume 71, Issue 6, 1 1 1987, Pages 599-603 Pharmacokinetics of high-dose teniposide. Holthuis JJ, de Vries LG, Postmus PE, van Oort WW, Verleun H, Hulshoff A, Sleijfer DT, Mulder NH
This paper describes the pharmacokinetics of teniposide (VM-26) after being administered iv in high doses to eight cancer patients (maximum dose, 1.0 g/m2). VM-26 levels in plasma, urine, saliva, duodenal fluid, and cerebrospinal fluid were determined using high-performance liquid chromatography in combination with electrochemical detection. The plasma concentration-time curve of VM-26 showed a triphasic decay with a slow third phase in five patients, whereas in two patients the plasma concentra... Abstract
Cited 1 times since 1987 (0 per year) source: EuropePMC
Cancer treatment reports, Volume 71, Issue 2, 1 1 1987, Pages 155-159 Phase I and pharmacokinetic study of trans-N3P3Az2(NHMe)4. Mulder NH, Meijers WH, van der Meulen JD, Sleijfer DT, Uges DR, de Vries EG, Postmus PE, van de Grampel JC, Willemse PH
trans-N3P3Az2(NHMe)4, an aziridinyl-substituted cyclophosphazene, was tested for its toxicity, pharmacokinetic behavior, and cytostatic activity in a phase I study in 30 patients. A total of 66 courses of a single iv bolus injection were given in five dose steps. Toxicity consisted of leukocytopenia and thrombocytopenia, dose limiting at 70 mg/m2, mild anemia, and some nausea. Leukocyte and platelet count nadirs fell between 2 and 3 weeks, with recovery at 6 weeks. A tendency for cumulative thro... Abstract
Cited 1 times since 1987 (0 per year) source: EuropePMC
European journal of respiratory diseases. Supplement, Volume 149, 1 1 1987, Pages 65-71 High-dose etoposide for central nervous system metastases of small cell lung cancer. Preliminary results. Postmus PE, Haaxma-Reiche H, Sleijfer DT, Kleisbauer JP, ten Velde G, Kirkpatrick A
High-dose etoposide (1.0-1.5 g/m2) was given to 17 small cell lung cancer (SCLC) patients with metastases in the central nervous system. In 4 out of 9 evaluable patients with brain metastases and 4 out of 5 patients with meningeal carcinomatosis a response was seen. In all patients severe myelosuppression was observed. Three patients died of septicemia during the aplastic phase. Despite severe toxicity high-dose etoposide is potentially useful for CNS metastases of SCLC. Abstract
European journal of respiratory diseases. Supplement, Volume 149, 1 1 1987, Pages 29-36 Genome analysis of small cell lung cancer (SCLC) and clinical significance. Buys CH, Osinga J, van der Veen AY, Mooibroek H, van der Hout AH, de Leij L, Postmus PE, Carritt B
A chromosome analysis of three cell lines derived from SCLC showed deletions of the short arm of chromosome 3 with bands p21-p23 as the shortest region of overlap. Hybridization of a polymorphic 3p21 probe to DNA from leukocytes of seven SCLC patients revealed heterozygosity for two of them. In the tumours of both these patients the probe detected homozygosity. This suggests the presence of a mutant cancer gene in the short arm of chromosome 3 which might express itself and/or activate some onco... Abstract
European journal of respiratory diseases. Supplement, Volume 149, 1 1 1987, Pages 19-27 Intermediate filament expression in small cell lung cancer; poor correlation to in vitro data. Berendsen HH, de Ley L, Poppema S, Postmus PE, Sluiter HJ, The TH
A panel of monoclonal antibodies, detecting different intermediate sized filament proteins, was prospectively applied on all specimens derived from S.C.L.C. patients attending our clinic in 1985. Reactivity with the antibodies was subsequently correlated to clinical data. The results indicate a heterogeneous pattern of reactivity of the assessed antibodies. However this heterogeneity is not a straightforward extension of the intermediate sized filament expression in SCLC cell lines. Abstract
Cited 5 times since 1987 (0.1 per year) source: EuropePMC
European journal of cancer & clinical oncology, Volume 23, Issue 1, 1 1 1987, Pages 55-60 In vitro chemosensitivity of human lung cancer for vindesine. De Vries EG, Meijer C, Mulder NH, Postmus PE
Firstly, the effect of Vindesine was studied on four different human lung carcinoma cell lines (two small cell, one adeno and one squamous cell) with the Fast Green dye exclusion assay (FGA) and the clonogenic assay. Both methods demonstrate a clear dose response relationship and the estimated drug efficacy is similar for both assays. In the cell lines with the longest doubling time a plateau was reached in the FGA, most probably due to the short culture time in this assay. Secondly, the effect... Abstract
Cited 3 times since 1987 (0.1 per year) source: EuropePMC
Journal of cancer research and clinical oncology, Volume 113, Issue 1, 1 1 1987, Pages 99-100 Twice weekly vindesine, a phase II study in lung cancer. Postmus PE, Mulder NH, Schipper DL, de Vries EG
Vindesine 1.75 mg/m2, twice weekly for 2 weeks followed by 2 weeks rest, was given to 26 lung cancer patients. In 6 patients a partial response was seen (23%). Neurotoxicity was present in 15 patients after 1 course; in 6 patients this was the reason for stopping therapy. This regimen has no advantage over weekly vindesine. Abstract
Cited 28 times since 1986 (0.7 per year) source: EuropePMC
European journal of cancer & clinical oncology, Volume 22, Issue 10, 1 1 1986, Pages 1149-1155 Pharmacokinetics of high dose etoposide (VP 16-213). Holthuis JJ, Postmus PE, Van Oort WJ, Hulshoff B, Verleun H, Sleijfer DT, Mulder NH
This paper describes the pharmacokinetics of etoposide in cancer patients after high dose administration (up to 3.5 g/m2). High performance liquid chromatography with electrochemical detection was used to determine etoposide, cis etoposide and the glucuronide of etoposide in plasma, bile, cerebro-spinal fluid, urine, saliva and ascites, the detection limit being 2 ng etoposide/ml plasma. The plasma concentration time curve shows a tri-phasic decay. The terminal phase is very slow. It was conclud... Abstract
Cited 3 times since 1986 (0.1 per year) source: EuropePMC
Chest, Volume 90, Issue 2, 1 1 1986, Pages 298-299 A family with lobus venae azygos. Postmus PE, Kerstjens JM, Breed A, vd Jagt E
Lobus venae azygos was found in five out of 12 members of one family. There is vertical transmission of the abnormality through three generations. The mode of inheritance is probably autosomal dominant. Abstract
Cited 4 times since 1986 (0.1 per year) source: EuropePMC
Cancer treatment reports, Volume 70, Issue 5, 1 1 1986, Pages 595-598 High-dose teniposide for refractory malignancies: a phase I study. de Vries EG, Mulder NH, Postmus PE, Vriesendorp R, Willemse PH, Sleijfer DT
To evaluate the dose-limiting toxicity of teniposide (VM-26), a phase I study was conducted. VM-26, a semisynthetic podophyllotoxin derivative, was administered on 3 consecutive days. The initial total dose per course was 0.3 g/m2, with dose escalation to 0.6 and 1 g/m2. The most prominent side effects observed were severe skin rash in all three patients in the highest dose group and a dose-dependent degree of leukocytopenia and thrombocytopenia. In the highest dose group the leukocyte count in... Abstract
Cited 1 times since 1986 (0 per year) source: EuropePMC
European journal of respiratory diseases, Volume 68, Issue 4, 1 1 1986, Pages 279-285 No response improvement after sequential chemotherapy for small cell lung cancer. Postmus PE, Sleijfer DT, Meinesz AF, Kerstjens HA, Lo GT, Sluiter HJ
In a phase II study in patients with small cell lung cancer (SCLC) the combination of cyclophosphamide, cisplatinum and etoposide was found to be active, the response rate was 91% (30% CR, 61% PR) in the whole group. In 40 limited disease patients 19 CR (48%) and 20 PR (50%) were seen, whereas in 30 extensive disease patients only 2 CR (7%) and 23 PR (77%) were reached. Adding a second combination of doxorubicin, vincristine and procarbazine resulted in response improvement in only two patients.... Abstract
Cited 5 times since 1986 (0.1 per year) source: EuropePMC
European journal of respiratory diseases, Volume 68, Issue 2, 1 1 1986, Pages 151-154 Irresectable bronchial carcinoid with a 32-year natural history. A report of two cases treated with Neodymium-YAG-laser, initially misinterpreted as small cell lung cancer. Berendsen HH, Postmus PE, Edens ET, Sluiter HJ
Two patients are described with bronchial carcinoid. In both, the initial diagnosis was small cell lung carcinoma (SCLC). This diagnosis was discordant with the clinical course; a second evaluation yielded the diagnosis of carcinoid. Good palliation was achieved with YAG-laser therapy. Abstract
Cited 15 times since 1986 (0.4 per year) source: EuropePMC
Cancer, Volume 57, Issue 1, 1 1 1986, Pages 60-63 Diagnostic application of a monoclonal antibody against small cell lung cancer. Postmus PE, Hirschler-Schulte TJ, De Leij L, Poppema S, Elema JE, Edens ET, Mesander G, Sluiter HJ, The TH
A monoclonal antibody (MOC-1) directed against an antigen present in small cell lung cancer (SCLC) was used for diagnostic purposes. After screening of biopsy specimens of lung tumors, MOC-1 was found to react with SCLC (n = 10) and adenocarcinoma of the lung (4 of 9 cases). Except for a few cells in a poorly differentiated tumor, the reaction with squamous cell cancer was negative (n = 6). Staining with MOC-1 by an immunoperoxidase technique on imprints of biopsy specimens procured by rigid bro... Abstract
Cited 2 times since 1986 (0.1 per year) source: EuropePMC
The Netherlands journal of medicine, Volume 29, Issue 11, 1 1 1986, Pages 359-364 High-dosage chemotherapy with autologous bone marrow reinfusion in the treatment of patients with solid tumours. The Groningen experience, 1981-1986. Mulder NH, Mulder PO, Van der Geest S, Halie MR, Maas A, Orie JL, Postmus PE, Sleijfer DT, Smit Sibinga CT, De Vries EG
Cited 91 times since 1985 (2.4 per year) source: EuropePMC
Cancer research, Volume 45, Issue 12 Pt 1, 1 1 1985, Pages 6024-6033 Characterization of three new variant type cell lines derived from small cell carcinoma of the lung. de Leij L, Postmus PE, Buys CH, Elema JD, Ramaekers F, Poppema S, Brouwer M, van der Veen AY, Mesander G, The TH
Three new, well growing cell lines (GLC-1, GLC-2, and GLC-3) have been established from small cell lung carcinoma (SCLC) and characterized. A subclone (GLC-1-M13) markedly different from its parent line GLC-1 was also isolated and characterized. Cytogenetic analysis of the cell lines revealed deletions in the short arm of chromosome 3 as a most consistent chromosomal aberration. The deleted region was not identical in all metaphases, 3p(21-23) being the shortest region of overlap. Despite their... Abstract
Cited 2 times since 1985 (0.1 per year) source: EuropePMC
European journal of cancer & clinical oncology, Volume 21, Issue 12, 1 1 1985, Pages 1555-1556 Phase one study of twice-weekly vindesine. Mulder NH, Postmus PE, Sleijfer DT, de Vries EG, Willemse PH
Cited 2 times since 1985 (0.1 per year) source: EuropePMC
European journal of cancer & clinical oncology, Volume 21, Issue 12, 1 1 1985, Pages 1467-1470 High-dose cyclophosphamide and high-dose VP 16-213 for recurrent or refractory small cell lung cancer. A phase II study. Postmus PE, Mulder NH, de Vries-Hospers HG, Mulder PO, Maas A, Meinesz AF, Sleijfer DT, de Vries EG
In nine patients with recurrent or refractory small cell lung cancer a phase II study with high-dose cyclophosphamide and high-dose VP 16-213 with autologous bone marrow transplantation was performed. The regimen used was based on a previously reported phase I study. In eight of the nine evaluable patients a response was seen (six PR and two CR). One patient died of treatment related toxicity. Infection is the most important toxicity. The response duration was short. This combination is a suitab... Abstract
Chest, Volume 88, Issue 4, 1 1 1985, Pages 635-636 Endoscopic treatment of a whistling middle-lobe bronchus. Hirschler-Schulte CJ, Postmus PE, van Overbeek JJ
A 32-year old man presented with dyspnea and a loud inspiratory wheeze. Examination revealed a nonfibrous, fissure-shaped entrance to the middle-lobe bronchus. The cause of this stenosis was unclear. Endoscopic treatment consisted of splitting the spur and resulted in complete disappearance of the wheeze. Abstract
Cited 2 times since 1985 (0.1 per year) source: EuropePMC
European journal of radiology, Volume 5, Issue 2, 1 1 1985, Pages 99-103 DSA--a helpful tool in diagnosis of aberrant left pulmonary artery (vascular sling) in adults. Mooyaart EL, Boomsma JH, Postmus PE, Formanek GA
Two new adult patients with aberrant origin of the left pulmonary artery from the right pulmonary artery--pulmonary artery sling--are described, totalling the published adult cases to eight. Differentiation from a mediastinal mass closely mimicking this vascular anomaly is discussed. For the definitive diagnosis, digital subtraction angiography was applied for the first time. The clearest demonstration of the anatomy is in 20-25 degrees RPO and 20-25 degrees sitting position. The aberrant left p... Abstract
Cited 42 times since 1985 (1.1 per year) source: EuropePMC
Cancer research, Volume 45, Issue 5, 1 1 1985, Pages 2192-2200 Neuroendocrine differentiation antigen on human lung carcinoma and Kulchitski cells. de Leij L, Poppema S, Nulend JK, ter Haar A, Schwander E, Ebbens F, Postmus PE, The TH
In the normal lung, a subset of cells with a histological appearance consistent with that of Kulchitski cells are the only lung cells reacting with a monoclonal antibody (MOC-1) raised against a human small cell lung carcinoma-derived cell line. Outside the lung, a subset of normal endocrine cells (in the adrenal, thyroid, ovary, and pancreas) as well as neural cells (brain and peripheral Schwann cells) also express the antigen detected by MOC-1 (named MOC-1-related antigen). Some of these posit... Abstract